PMID- 27118163
OWN - NLM
STAT- MEDLINE
DCOM- 20180321
LR  - 20220408
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Print)
IS  - 1056-8727 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Aug
TI  - Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and 
      change over time.
PG  - 1123-8
LID - S1056-8727(16)30088-5 [pii]
LID - 10.1016/j.jdiacomp.2016.03.032 [doi]
AB  - AIMS: To document the prevalence and 9-month incidence of elevated diabetes 
      distress (DD) and the stability of DD over time using both single threshold and 
      minimal clinically important differences (MCID) approaches. METHODS: Adults with 
      type 1 diabetes (T1D) (N=224) completed the 28-item T1-Diabetes Distress Scale 
      (T1-DDS) at baseline and 9months. A T1-DDS threshold was identified with spline 
      analysis and MCID was calculated from the standard error of measurement. RESULTS: 
      Analyses supported a cut-point of >/=2.0 for elevated DD. The prevalence and 
      9-month incidence of elevated DD was 42.1% and 54.4%, respectively. MCID was 
      +/-0.19 but varied by subscale (.26 to .50). Elevated DD was stable: only 20% 
      crossed 2.0 over 9months. MCID analyses showed that change also occurred among 
      those who remained either below or above 2.0 over time. Change varied by source 
      of distress, with Powerlessness the most prevalent and stable. Using MCID, only 
      participant age, gender and number of complications predicted change. 
      CONCLUSIONS: The prevalence, 9-month incidence and stability of elevated DD are 
      high among adults with T1D, with change based on source of DD. We propose a 
      combined cut-point/MCID framework for measuring change in DD, since each approach 
      reflects unique characteristics of change over time.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Fisher, Lawrence
AU  - Fisher L
AD  - Department of Family & Community Medicine, University of California,s San 
      Francisco, San Francisco, CA, USA. Electronic address: larry.fisher@ucsf.edu.
FAU - Hessler, Danielle
AU  - Hessler D
AD  - Department of Family & Community Medicine, University of California,s San 
      Francisco, San Francisco, CA, USA.
FAU - Polonsky, William
AU  - Polonsky W
AD  - Department of Psychiatry, University of California, San Diego, San Diego, CA, 
      USA; Behavioral Diabetes Institute, San Diego, CA, USA.
FAU - Strycker, Lisa
AU  - Strycker L
AD  - Oregon Research Institute, Eugene, OR, USA.
FAU - Masharani, Umesh
AU  - Masharani U
AD  - Department of Medicine, University of California, San Francisco, San Francisco, 
      CA, USA.
FAU - Peters, Anne
AU  - Peters A
AD  - University of Southern California, Los Angeles, CA, USA.
LA  - eng
GR  - R01 DK094863/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20160404
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
SB  - IM
MH  - Adult
MH  - Diabetes Mellitus, Type 1/*psychology
MH  - Emotions
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Stress, Psychological/*epidemiology
PMC - PMC4949147
MID - NIHMS776211
OTO - NOTNLM
OT  - Change over time
OT  - Diabetes distress
OT  - Incidence
OT  - Predictors of change
OT  - Prevalence
COIS- Competing Interests No author reported a conflict of interest. Lawrence Fisher: 
      consultant to or advisory board member for Roche Diagnostics, Elli Lilly, Novo 
      Nordisk, Sanofi, Abbott Diabetes Care; William Polonsky: consultant or advisory 
      board with Sanofi, Novo Nordisk, Elli Lilly, Dexcom, Abbott, J&J, Boehringer 
      Ingelheim, Takeda, Roche; Anne Peters: consultant or advisory board with Amgen, 
      Abbott Diabetes Care, Becton Dickinson, Biodel, Bristol Myers 
      Squibb/Astra-Zeneca, Janssen, Lexicon, Lilly, Medtronic Minimed, Novo Nordisk, 
      OptumRx, sanofi, Takeda, Thermalin. Speakers bureau - Bristol Myers 
      Squibb/Astra-Zeneca, Novo Nordisk, Janssen.
EDAT- 2016/04/28 06:00
MHDA- 2018/03/22 06:00
PMCR- 2017/08/01
CRDT- 2016/04/28 06:00
PHST- 2016/02/23 00:00 [received]
PHST- 2016/03/23 00:00 [revised]
PHST- 2016/03/24 00:00 [accepted]
PHST- 2016/04/28 06:00 [entrez]
PHST- 2016/04/28 06:00 [pubmed]
PHST- 2018/03/22 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - S1056-8727(16)30088-5 [pii]
AID - 10.1016/j.jdiacomp.2016.03.032 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2016 Aug;30(6):1123-8. doi: 
      10.1016/j.jdiacomp.2016.03.032. Epub 2016 Apr 4.